When a patient with heart disease is in need of a vascular graft but doesn't have any viable veins or arteries in his or her own body, surgeons can rely on synthetic, tissue-engineering grafts.

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side ...

Please provide your email address to receive an email when new articles are posted on . WAIKOLOA, Hawaii — In this video from Orthopedics Today Hawaii, John M. Tokish, MD, spoke about moving toward an ...

A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants ...

Please provide your email address to receive an email when new articles are posted on . Adequate stability of vascularized bone graft constructs is critical to successful treatment of proximal pole of ...

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in ...

A new study led by UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease (GVHD), an ...